The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
09 Oct 2024
Historique:
received: 28 04 2023
accepted: 14 08 2024
medline: 10 10 2024
pubmed: 10 10 2024
entrez: 9 10 2024
Statut: aheadofprint

Résumé

Advanced urothelial cancer is a frequently lethal disease characterized by marked genetic heterogeneity

Identifiants

pubmed: 39385020
doi: 10.1038/s41586-024-07955-3
pii: 10.1038/s41586-024-07955-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Faltas, B. M. et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat. Genet. 48, 1490–1499 (2016).
pubmed: 27749842 pmcid: 5549141 doi: 10.1038/ng.3692
Hadi, K. et al. Distinct classes of complex structural variation uncovered across thousands of cancer genome graphs. Cell 183, 197–210.e32 (2020).
pubmed: 33007263 pmcid: 7912537 doi: 10.1016/j.cell.2020.08.006
Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704–712 (2015).
pubmed: 26091828 pmcid: 4497973 doi: 10.1158/2159-8290.CD-15-0344
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
pubmed: 32025018 pmcid: 7054213 doi: 10.1038/s41586-020-1943-3
Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970–976 (2013).
pubmed: 23852170 pmcid: 3789062 doi: 10.1038/ng.2702
Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012).
pubmed: 22608084 pmcid: 3414841 doi: 10.1016/j.cell.2012.04.024
Liu, W. et al. The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer. Cancer Res. 83, 506–520 (2023).
pubmed: 36480186 doi: 10.1158/0008-5472.CAN-22-2912
Pich, O. et al. The mutational footprints of cancer therapies. Nat. Genet. 51, 1732–1740 (2019).
pubmed: 31740835 pmcid: 6887544 doi: 10.1038/s41588-019-0525-5
Kucab, J. E. et al. A compendium of mutational signatures of environmental agents. Cell 177, 821–836.e16 (2019).
pubmed: 30982602 pmcid: 6506336 doi: 10.1016/j.cell.2019.03.001
Lawson, A. R. J. et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science 370, 75–82 (2020).
pubmed: 33004514 doi: 10.1126/science.aba8347
Li, R. et al. Macroscopic somatic clonal expansion in morphologically normal human urothelium. Science 370, 82–89 (2020).
pubmed: 33004515 doi: 10.1126/science.aba7300
Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122–128 (2020).
pubmed: 32025013 pmcid: 7054212 doi: 10.1038/s41586-019-1907-7
Gorelick, A. N. et al. Phase and context shape the function of composite oncogenic mutations. Nature 582, 100–103 (2020).
pubmed: 32461694 pmcid: 7294994 doi: 10.1038/s41586-020-2315-8
Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540–556.e25 (2017).
pubmed: 28988769 pmcid: 5687509 doi: 10.1016/j.cell.2017.09.007
Li, Y. et al. Patterns of somatic structural variation in human cancer genomes. Nature 578, 112–121 (2020).
pubmed: 32025012 pmcid: 7025897 doi: 10.1038/s41586-019-1913-9
Pecorino, L. T., Verhaak, R. G. W., Henssen, A. & Mischel, P. S. Extrachromosomal DNA (ecDNA): an origin of tumor heterogeneity, genomic remodeling, and drug resistance. Biochem. Soc. Trans. 50, 1911–1920 (2022).
pubmed: 36355400 pmcid: 9788557 doi: 10.1042/BST20221045
Deshpande, V. et al. Exploring the landscape of focal amplifications in cancer using AmpliconArchitect. Nat. Commun. 10, 392 (2019).
pubmed: 30674876 pmcid: 6344493 doi: 10.1038/s41467-018-08200-y
van Leen, E., Brückner, L. & Henssen, A. G. The genomic and spatial mobility of extrachromosomal DNA and its implications for cancer therapy. Nat. Genet. 54, 107–114 (2022).
pubmed: 35145302 doi: 10.1038/s41588-021-01000-z
Bao, L., Zhong, X., Yang, Y. & Yang, L. Starfish infers signatures of complex genomic rearrangements across human cancers. Nat. Cancer 3, 1247–1259 (2022).
pubmed: 35835961 pmcid: 11077613 doi: 10.1038/s43018-022-00404-y
Bergstrom, E. N. et al. Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. Nature 602, 510–517 (2022).
pubmed: 35140399 pmcid: 8850194 doi: 10.1038/s41586-022-04398-6
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
doi: 10.1038/s41586-020-1969-6
Kim, H. et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat. Genet. 52, 891–897 (2020).
pubmed: 32807987 pmcid: 7484012 doi: 10.1038/s41588-020-0678-2
Bertoli, C., Skotheim, J. M. & de Bruin, R. A. M. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol. 14, 518–528 (2013).
pubmed: 23877564 pmcid: 4569015 doi: 10.1038/nrm3629
Lange, J. T. et al. The evolutionary dynamics of extrachromosomal DNA in human cancers. Nat. Genet. 54, 1527–1533 (2022).
pubmed: 36123406 pmcid: 9534767 doi: 10.1038/s41588-022-01177-x
Dharanipragada, P. et al. Blocking genomic instability prevents acquired resistance to MAPK inhibitor therapy in melanoma. Cancer Discov. 13, 880–909 (2023).
pubmed: 36700848 pmcid: 10068459 doi: 10.1158/2159-8290.CD-22-0787
Zhu, Y. et al. Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription. Cancer Cell 39, 694–707.e7 (2021).
pubmed: 33836152 pmcid: 8119378 doi: 10.1016/j.ccell.2021.03.006
Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell 184, 2239–2254.e39 (2021).
pubmed: 33831375 pmcid: 8054914 doi: 10.1016/j.cell.2021.03.009
Thomsen, M. B. H. et al. Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. Sci. Rep. 7, 11702 (2017).
pubmed: 28916750 pmcid: 5600970 doi: 10.1038/s41598-017-11291-0
Jamal-Hanjani, M. et al. Tracking the evolution of non–small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
pubmed: 28445112 doi: 10.1056/NEJMoa1616288
Natesan, D. et al. APOBEC mutational signature and tumor mutational burden as predictors of clinical outcomes and treatment response in patients with advanced urothelial cancer. Front. Oncol. 12, 816706 (2022).
pubmed: 35321431 pmcid: 8935010 doi: 10.3389/fonc.2022.816706
Green, A. M. et al. APOBEC3A damages the cellular genome during DNA replication. Cell Cycle 15, 998–1008 (2016).
pubmed: 26918916 pmcid: 4889253 doi: 10.1080/15384101.2016.1152426
Petljak, M. et al. Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis. Cell 176, 1282–1294.e20 (2019).
pubmed: 30849372 pmcid: 6424819 doi: 10.1016/j.cell.2019.02.012
Jones, R. T. et al. NPEPPS is a druggable driver of platinum resistance. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-23-1976 (2024).
Chang, Y.-W. et al. Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects. Oncotarget 5, 3823–3835 (2014).
pubmed: 25003617 pmcid: 4116523 doi: 10.18632/oncotarget.1709
Hua, Y. et al. Slow down to stay alive: HER4 protects against cellular stress and confers chemoresistance in neuroblastoma. Cancer 118, 5140–5154 (2012).
pubmed: 22415601 doi: 10.1002/cncr.27496
Bauvois, B. et al. Activation of interferon signaling in chronic lymphocytic leukemia cells contributes to apoptosis resistance via a JAK-Src/STAT3/Mcl-1 signaling pathway. Biomedicines 9, 188 (2021).
pubmed: 33668421 pmcid: 7918075 doi: 10.3390/biomedicines9020188
Lin, W. et al. Discovery and validation of nitroxoline as a novel STAT3 inhibitor in drug-resistant urothelial bladder cancer. Int. J. Biol. Sci. 17, 3255–3267 (2021).
pubmed: 34421363 pmcid: 8375225 doi: 10.7150/ijbs.63125
Juliachs, M. et al. The PDGFRβ–AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin. Cancer Res. 20, 658–667 (2014).
pubmed: 24277456 doi: 10.1158/1078-0432.CCR-13-1131
Ji, Y. et al. Anlotinib exerts inhibitory effects against cisplatin-resistant ovarian cancer in vitro and in vivo. Molecules 27, 8873 (2022).
pubmed: 36558006 pmcid: 9785832 doi: 10.3390/molecules27248873
Baym, M. et al. Spatiotemporal microbial evolution on antibiotic landscapes. Science 353, 1147–1151 (2016).
pubmed: 27609891 pmcid: 5534434 doi: 10.1126/science.aag0822
Turner, K. M. et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543, 122–125 (2017).
pubmed: 28178237 pmcid: 5334176 doi: 10.1038/nature21356
Wang, T., Zhang, H., Zhou, Y. & Shi, J. Extrachromosomal circular DNA: a new potential role in cancer progression. J. Transl. Med. 19, 257 (2021).
pubmed: 34112178 pmcid: 8194206 doi: 10.1186/s12967-021-02927-x
Ilić, M., Zaalberg, I. C., Raaijmakers, J. A. & Medema, R. H. Life of double minutes: generation, maintenance, and elimination. Chromosoma 131, 107–125 (2022).
pubmed: 35487993 pmcid: 9470669 doi: 10.1007/s00412-022-00773-4
Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47–58 (2024).
pubmed: 37870536 doi: 10.1200/JCO.23.02005
Chen, Y., Qiu, Q., She, J. & Yu, J. Extrachromosomal circular DNA in colorectal cancer: biogenesis, function and potential as therapeutic target. Oncogene 42, 941–951 (2023).
pubmed: 36859558 pmcid: 10038807 doi: 10.1038/s41388-023-02640-7
Noer, J. B., Hørsdal, O. K., Xiang, X., Luo, Y. & Regenberg, B. Extrachromosomal circular DNA in cancer: history, current knowledge, and methods. Trends Genet. 38, 766–781 (2022).
pubmed: 35277298 doi: 10.1016/j.tig.2022.02.007
Shoshani, O. et al. Chromothripsis drives the evolution of gene amplification in cancer. Nature 591, 137–141 (2021).
pubmed: 33361815 doi: 10.1038/s41586-020-03064-z
Maciejowski, J. et al. APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis. Nat. Genet. 52, 884–890 (2020).
pubmed: 32719516 pmcid: 7484228 doi: 10.1038/s41588-020-0667-5
Maciejowski, J., Li, Y., Bosco, N., Campbell, P. J. & de Lange, T. Chromothripsis and kataegis induced by telomere crisis. Cell 163, 1641–1654 (2015).
pubmed: 26687355 pmcid: 4687025 doi: 10.1016/j.cell.2015.11.054
Chen, J. P. et al. scCircle-seq unveils the diversity and complexity of extrachromosomal circular DNAs in single cells. Nat. Commun. 15, 1768 (2024).
pubmed: 38409079 pmcid: 10897160 doi: 10.1038/s41467-024-45972-y
Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596–614.e14 (2021).
pubmed: 33508232 pmcid: 7933824 doi: 10.1016/j.cell.2021.01.002
Sjödahl, G., Eriksson, P., Liedberg, F. & Höglund, M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J. Pathol. 242, 113–125 (2017).
pubmed: 28195647 pmcid: 5413843 doi: 10.1002/path.4886
Jirawatnotai, S., Hu, Y., Livingston, D. M. & Sicinski, P. Proteomic identification of a direct role for cyclin D1 in DNA damage repair. Cancer Res. 72, 4289–4293 (2012).
pubmed: 22915759 pmcid: 3432743 doi: 10.1158/0008-5472.CAN-11-3549
Seiler, R., Thalmann, G. N., Rotzer, D., Perren, A. & Fleischmann, A. CCND1/cyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. Mod. Pathol. 27, 87–95 (2014).
pubmed: 23887292 doi: 10.1038/modpathol.2013.125
Arora, K. et al. Deep whole-genome sequencing of 3 cancer cell lines on 2 sequencing platforms. Sci. Rep. 9, 19123 (2019).
pubmed: 31836783 pmcid: 6911065 doi: 10.1038/s41598-019-55636-3
Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https://doi.org/10.48550/arXiv.1303.3997 (2013).
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199 pmcid: 2928508 doi: 10.1101/gr.107524.110
Benjamin, D. et al. Calling somatic SNVs and Indels with Mutect2. Preprint at bioRxiv https://doi.org/10.1101/861054 (2019).
Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591–594 (2018).
pubmed: 30013048 doi: 10.1038/s41592-018-0051-x
Narzisi, G. et al. Genome-wide somatic variant calling using localized colored de Bruijn graphs. Commun. Biol. 1, 20 (2018).
pubmed: 30271907 pmcid: 6123722 doi: 10.1038/s42003-018-0023-9
Wala, J. A. et al. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 28, 581–591 (2018).
pubmed: 29535149 pmcid: 5880247 doi: 10.1101/gr.221028.117
Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220–1222 (2016).
pubmed: 26647377 doi: 10.1093/bioinformatics/btv710
Layer, R. M., Chiang, C., Quinlan, A. R. & Hall, I. M. LUMPY: a probabilistic framework for structural variant discovery. Genome Biol. 15, R84 (2014).
pubmed: 24970577 pmcid: 4197822 doi: 10.1186/gb-2014-15-6-r84
Emde, A.-K. et al. Detecting genomic indel variants with exact breakpoints in single- and paired-end sequencing data using SplazerS. Bioinformatics 28, 619–627 (2012).
pubmed: 22238266 doi: 10.1093/bioinformatics/bts019
Hubbard, T. The Ensembl genome database project. Nucleic Acids Res. 30, 38–41 (2002).
pubmed: 11752248 pmcid: 99161 doi: 10.1093/nar/30.1.38
Tate, J. G. et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 47, D941–D947 (2019).
pubmed: 30371878 doi: 10.1093/nar/gky1015
The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68–74 (2015).
doi: 10.1038/nature15393
Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
pubmed: 29165669 doi: 10.1093/nar/gkx1153
Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense mutations using PolyPhen‐2. Curr. Protoc. Hum. Genet. https://doi.org/10.1002/0471142905.hg0720s76 (2013).
Vaser, R., Adusumalli, S., Leng, S. N., Sikic, M. & Ng, P. C. SIFT missense predictions for genomes. Nat. Protoc. 11, 1–9 (2016).
pubmed: 26633127 doi: 10.1038/nprot.2015.123
Shihab, H. A. et al. Ranking non-synonymous single nucleotide polymorphisms based on disease concepts. Hum. Genomics 8, 11 (2014).
pubmed: 24980617 pmcid: 4083756 doi: 10.1186/1479-7364-8-11
Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
pmcid: 5018207 doi: 10.1038/nature19057
Sherry, S. T. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308–311 (2001).
pubmed: 11125122 pmcid: 29783 doi: 10.1093/nar/29.1.308
McLaren, W. et al. The Ensembl variant effect predictor. Genome Biol. 17, 122 (2016).
pubmed: 27268795 pmcid: 4893825 doi: 10.1186/s13059-016-0974-4
MacDonald, J. R., Ziman, R., Yuen, R. K. C., Feuk, L. & Scherer, S. W. The Database of Genomic Variants: a curated collection of structural variation in the human genome. Nucleic Acids Res. 42, D986–D992 (2014).
pubmed: 24174537 doi: 10.1093/nar/gkt958
Collins, R. L. et al. A structural variation reference for medical and population genetics. Nature 581, 444–451 (2020).
pubmed: 32461652 pmcid: 7334194 doi: 10.1038/s41586-020-2287-8
Raine, K. M. et al. ascatNgs: identifying somatically acquired copy‐number alterations from whole‐genome sequencing data. Curr. Protoc. Bioinformatics 56, 15.9.1–15.9.17 (2016).
pubmed: 27930809 doi: 10.1002/cpbi.17
Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64–70 (2015).
pubmed: 25319062 doi: 10.1093/annonc/mdu479
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
pubmed: 26899170 pmcid: 4762164 doi: 10.1186/s13059-016-0893-4
Kasar, S. et al. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat. Commun. 6, 8866 (2015).
pubmed: 26638776 doi: 10.1038/ncomms9866
Jupe, S. Chromatin modifying enzymes. Reactome https://doi.org/10.3180/react_172633.1 (2014).
Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications—miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10, 457–469 (2010).
pubmed: 20574448 pmcid: 3262678 doi: 10.1038/nrc2876
Gui, Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875–878 (2011).
pubmed: 21822268 pmcid: 5373841 doi: 10.1038/ng.907
Shen, H. & Laird, P. W. Interplay between the cancer genome and epigenome. Cell 153, 38–55 (2013).
pubmed: 23540689 pmcid: 3648790 doi: 10.1016/j.cell.2013.03.008
Shyr, C. et al. FLAGS, frequently mutated genes in public exomes. BMC Med. Genomics 7, 64 (2014).
The FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoter-level mammalian expression atlas. Nature 507, 462–470 (2014).
doi: 10.1038/nature13182
Dalby, M., Rennie, S. & Andersson, R. Fantom5 transcribed enhancers In hg38. Zenodo https://doi.org/10.5281/zenodo.556775 (2017).
Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934–947 (2013).
pubmed: 24119843 doi: 10.1016/j.cell.2013.09.053
Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).
pubmed: 23586463 pmcid: 3637064 doi: 10.1186/1471-2105-14-128
Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
pubmed: 27141961 pmcid: 4987924 doi: 10.1093/nar/gkw377
Xie, Z. et al. Gene Set Knowledge Discovery with Enrichr. Curr. Protoc. 1, e90 (2021).
pubmed: 33780170 pmcid: 8152575 doi: 10.1002/cpz1.90
Tarabichi, M. et al. A practical guide to cancer subclonal reconstruction from DNA sequencing. Nat. Methods 18, 144–155 (2021).
pubmed: 33398189 pmcid: 7867630 doi: 10.1038/s41592-020-01013-2
Popic, V. et al. Fast and scalable inference of multi-sample cancer lineages. Genome Biol. 16, 91 (2015).
pubmed: 25944252 pmcid: 4501097 doi: 10.1186/s13059-015-0647-8
Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911–917 (2018).
pubmed: 30337457 pmcid: 6298579 doi: 10.1126/science.aau3879
Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041.e21 (2017).
pubmed: 29056346 pmcid: 5720395 doi: 10.1016/j.cell.2017.09.042
Martincorena, I. et al. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880–886 (2015).
pubmed: 25999502 pmcid: 4471149 doi: 10.1126/science.aaa6806
Herms, A. & Jones, P. H. Somatic mutations in normal tissues: new perspectives on early carcinogenesis. Annu. Rev. Cancer Biol. 7, 189–205 (2023).
doi: 10.1146/annurev-cancerbio-061421-012447
Deshpande, A., Walradt, T., Hu, Y., Koren, A. & Imielinski, M. Robust foreground detection in somatic copy number data. Preprint at bioRxiv https://doi.org/10.1101/847681 (2019).
Imielinski, M., Guo, G. & Meyerson, M. Insertions and deletions target lineage-defining genes in human cancers. Cell 168, 460–472.e14 (2017).
pubmed: 28089356 pmcid: 5564321 doi: 10.1016/j.cell.2016.12.025
Zhou, M. et al. Patterns of structural variation define prostate cancer across disease states. JCI Insight 7, e161370 (2022).
pubmed: 35943799 pmcid: 9536266 doi: 10.1172/jci.insight.161370
Lee, B. T. et al. The UCSC Genome Browser database: 2022 update. Nucleic Acids Res. 50, D1115–D1122 (2022).
pubmed: 34718705 doi: 10.1093/nar/gkab959
Sondka, Z. et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696–705 (2018).
pubmed: 30293088 pmcid: 6450507 doi: 10.1038/s41568-018-0060-1
Bergstrom, E. N., Kundu, M., Tbeileh, N. & Alexandrov, L. B. Examining clustered somatic mutations with SigProfilerClusters. Bioinformatics 38, 3470–3473 (2022).
pubmed: 35595234 pmcid: 9237733 doi: 10.1093/bioinformatics/btac335
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 doi: 10.1093/bioinformatics/bts635
Veeneman, B. A., Shukla, S., Dhanasekaran, S. M., Chinnaiyan, A. M. & Nesvizhskii, A. I. Two-pass alignment improves novel splice junction quantification. Bioinformatics 32, 43–49 (2016).
pubmed: 26519505 doi: 10.1093/bioinformatics/btv642
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
pubmed: 24227677 doi: 10.1093/bioinformatics/btt656
Zhang, Y., Parmigiani, G. & Johnson, W. E. ComBat-seq: batch effect adjustment for RNA-seq count data. NAR Genom. Bioinform. 2, lqaa078 (2020).
pubmed: 33015620 pmcid: 7518324 doi: 10.1093/nargab/lqaa078
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304.e6 (2018).
pubmed: 29625048 pmcid: 5957518 doi: 10.1016/j.cell.2018.03.022
Rosenbloom, K. R. et al. ENCODE data in the UCSC Genome browser: year 5 update. Nucleic Acids Res. 41, D56–D63 (2012).
pubmed: 23193274 pmcid: 3531152 doi: 10.1093/nar/gks1172
Luebeck, J. et al. AmpliconReconstructor integrates NGS and optical mapping to resolve the complex structures of focal amplifications. Nat. Commun. 11, 4374 (2020).
pubmed: 32873787 pmcid: 7463033 doi: 10.1038/s41467-020-18099-z
Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094–3100 (2018).
pubmed: 29750242 pmcid: 6137996 doi: 10.1093/bioinformatics/bty191
Danecek, P. et al. Twelve years of SAMtools and BCFtools. GigaScience 10, giab008 (2021).
pubmed: 33590861 pmcid: 7931819 doi: 10.1093/gigascience/giab008
Kolmogorov, M. et al. metaFlye: scalable long-read metagenome assembly using repeat graphs. Nat. Methods 17, 1103–1110 (2020).
pubmed: 33020656 pmcid: 10699202 doi: 10.1038/s41592-020-00971-x
Lufino, M. M., Edser, P. A. & Wade-Martins, R. Advances in high-capacity extrachromosomal vector technology: episomal maintenance, vector delivery, and transgene expression. Mol. Ther. 16, 1525–1538 (2008).
pubmed: 18628754 doi: 10.1038/mt.2008.156
Jin, C. et al. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer. EMBO Mol. Med. 8, 702–711 (2016).
pubmed: 27189167 pmcid: 4931286 doi: 10.15252/emmm.201505869
Hall, M. D. et al. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res. 74, 3913–3922 (2014).
pubmed: 24812268 pmcid: 4153432 doi: 10.1158/0008-5472.CAN-14-0247
Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).
pubmed: 29409532 pmcid: 5802054 doi: 10.1186/s13059-017-1382-0
Virshup, I., Rybakov, S., Theis, F. J., Angerer, P. & Wolf, F. A. anndata: annotated data. Preprint at bioRxiv https://doi.org/10.1101/2021.12.16.473007 (2021).
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
pubmed: 31740819 pmcid: 6884693 doi: 10.1038/s41592-019-0619-0
Liberzon, A. et al. The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969 doi: 10.1016/j.cels.2015.12.004
Fox, M. H. A model for the computer analysis of synchronous DNA distributions obtained by flow cytometry. Cytometry 1, 71–77 (1980).
pubmed: 7023881 doi: 10.1002/cyto.990010114
Cyrta, J. et al. Whole-genome characterization of myoepithelial carcinomas of the soft tissue. Cold Spring Harb. Mol. Case Stud. 8, a006227 (2022).
pubmed: 36577525 pmcid: 9808553 doi: 10.1101/mcs.a006227
Mosquera, J. M. et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1–10 (2013).
pubmed: 23358695 pmcid: 3556934 doi: 10.1593/neo.121550
Green, A. M. et al. Cytosine deaminase APOBEC3A sensitizes leukemia cells to inhibition of the DNA replication checkpoint. Cancer Res. 77, 4579–4588 (2017).
pubmed: 28655787 pmcid: 5581702 doi: 10.1158/0008-5472.CAN-16-3394
Shin, K.-J. et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc. Natl Acad. Sci. USA 103, 13759–13764 (2006).
pubmed: 16945906 pmcid: 1557799 doi: 10.1073/pnas.0606179103
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
pubmed: 22743772 doi: 10.1038/nmeth.2019
Goglia, A. G. et al. Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors. Mol. Cancer Ther. 14, 326–342 (2015).
pubmed: 25512618 doi: 10.1158/1535-7163.MCT-14-0765
Nguyen, D. D. et al. The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution. Zenodo https://doi.org/10.5281/zenodo.11121869 (2024).

Auteurs

Duy D Nguyen (DD)

Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

William F Hooper (WF)

New York Genome Center, New York, NY, USA.

Weisi Liu (W)

Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Timothy R Chu (TR)

New York Genome Center, New York, NY, USA.

Heather Geiger (H)

New York Genome Center, New York, NY, USA.

Jennifer M Shelton (JM)

New York Genome Center, New York, NY, USA.

Minita Shah (M)

New York Genome Center, New York, NY, USA.

Zoe R Goldstein (ZR)

New York Genome Center, New York, NY, USA.

Lara Winterkorn (L)

New York Genome Center, New York, NY, USA.

Adrienne Helland (A)

New York Genome Center, New York, NY, USA.

Michael Sigouros (M)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.

Jyothi Manohar (J)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.

Jenna Moyer (J)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.

Majd Al Assaad (M)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.

Alissa Semaan (A)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.

Sandra Cohen (S)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.

Florencia Madorsky Rowdo (F)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.

David Wilkes (D)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.

Mohamed Osman (M)

Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Rahul R Singh (RR)

Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Andrea Sboner (A)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.

Henkel L Valentine (HL)

Nuclear Dynamics and Cancer program, Fox Chase Cancer Center, Philadelphia, PA, USA.

Phillip Abbosh (P)

Nuclear Dynamics and Cancer program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Department of Urology, Einstein Healthcare Network, Philadelphia, PA, USA.

Scott T Tagawa (ST)

Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Department of Urology, Weill Cornell Medicine, New York, NY, USA.

David M Nanus (DM)

Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Department of Urology, Weill Cornell Medicine, New York, NY, USA.

Jones T Nauseef (JT)

Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Cora N Sternberg (CN)

Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Ana M Molina (AM)

Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Douglas Scherr (D)

Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Department of Urology, Weill Cornell Medicine, New York, NY, USA.

Giorgio Inghirami (G)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Juan Miguel Mosquera (JM)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Olivier Elemento (O)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.

Nicolas Robine (N)

New York Genome Center, New York, NY, USA.

Bishoy M Faltas (BM)

Department of Medicine, Weill Cornell Medicine, New York, NY, USA. bmf9003@med.cornell.edu.
Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA. bmf9003@med.cornell.edu.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. bmf9003@med.cornell.edu.
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA. bmf9003@med.cornell.edu.
Department of Cell and Developmental Biology, Weill Cornell Medicine, New York, NY, USA. bmf9003@med.cornell.edu.

Classifications MeSH